Discovering new antibiotics is a major scientific challenge, made increasingly urgent by the continued 28 development of resistance in bacterial pathogens. A fundamental understanding of the mechanisms of 29 bacterial antibiotic resistance will be vital for the future discovery or design of new, more effective 30 antibiotics. We have exploited our intimate knowledge of the molecular mechanism of glycopeptide 31 antibiotic resistance in the harmless bacterium Streptomyces coelicolor to develop a new two-step cell 32 wall bioactivity screen that efficiently identified a new actinomycete strain containing a previously 33 uncharacterized glycopeptide synthetic gene cluster. The screen first identifies natural product extracts 34 capable of triggering a generalized cell wall stress response mechanism, then subsequently specifically 35 selects for glycopeptide antibacterials by assaying for induction of glycopeptide resistance genes. In 36 this study, we have established a diverse natural product extract library from actinomycetes strains 37 isolated from locations with widely varying climates and ecologies and screened them using the novel 38 two-step bioassay system. The bioassay ultimately identified a single strain harboring the previously 39 unidentified biosynthetic gene cluster for the glycopeptide ristocetin providing a proof-of-principle for 40
INTRODUCTION 48
Recent years have seen ever increasing numbers of cases of infections caused by drug-resistant 50 bacteria, creating an urgent need for new and improved antibiotics (1). Unfortunately, traditional 51 antibiotic research and development has decreased during this period leading to a reduction in the 52 antibiotic discovery pipeline and a developing public health crisis. Understanding how antibiotics can 53 fail to be active is vital knowledge for the development of future novel antimicrobials. Such 54 information is often linked intimately to the drug's mode of action, and therefore can provide unique 55 insights that can be used to help discover and design novel compounds, or to develop new ways of 56 prolonging the therapeutic usefulness of existing ones. Such efforts can be assisted by recent advances 57 in genetic engineering and synthetic biology approaches that will facilitate the targeted modification of 58 existing antibiotic structures (2). These techniques however rely on the supply of a diverse range of 59 well characterized antibiotic scaffold-modifying enzymes to be called upon to specifically expand the 60 chemical diversity of the natural structures available. The discovery of new enzyme activities can 61 therefore be seen as an important goal in itself, alongside the larger goal of identifying novel natural 62
antibiotics. 63
The bacterial cell wall is an important and validated target for antibacterial chemotherapy; it is 64 crucial for bacterial cell growth by providing a physical protective barrier between the cell and its 65 environment, and is an important mediator of the innate immune response during bacterial infections. 66
Antibiotics that inhibit bacterial cell wall biosynthesis are therefore clinically important in the 67 treatment of infectious diseases. Understanding bacterial cell wall biosynthesis has been the subject of 68 intensive study from the time of the discovery of penicillin, the first clinically available antibiotic 69 (Table S3) . After incubation at 30 °C and 280 rpm for 6 days in a 250 ml sterile flask 123 containing a 30 cm coiled stainless steel spring baffle, each culture broth was centrifuged for 5 min at 124 1,500 g. The supernatant was poured into 30 ml of ethyl acetate and extracted for 5 min by vortexing 125 vigorously. Following phase separation, the ethyl acetate layer was evaporated to dryness and re-126 dissolved in 3 ml methanol. The aqueous phase was mildly heated (60 °C) for 30 min to remove ethyl 127 acetate remained in aqueous phase and freeze-dried, then re-dissolved in 3 ml water. The cell pellet was 128 extracted with 3 ml of methanol by vigorous vortexing for 20 min then centrifuged for 5 min at 1,500 g 129 to remove cell debris. 30 μl aliquots of each extract were added to 96 well plates, freeze dried and 130 stored at 4 °C. Each actinomycete isolate consequently generates nine different extracts. The full 131 extract library currently consists of approximately 150,000 natural product extracts from over 15,000 132 different actinomycete strains. The library has been give the acronym ECUM (Extract Collection of 133
Useful Microorganisms) and is further described at www.ecum.or.kr. 134
135

Screening the extract library and isolation of MJM2582. 136
Each freeze-dried actinomycete extract aliquot from the 96 well plates was dissolved in 30 μl dimethyl 137 sulfoxide (DMSO) and 10 µl was used per screening assay. For the first-round screening using the 138 sigEp-neo fusion reporter system, approximately 10 7 spores of S. coelicolor M600 carrying pIJ6880 (a 139 multi-copy, promoter probe plasmid, pIJ486, carrying sigEp-neo fusion DNA; see Table S1 in the 140 supplemental material) were spread on 12 cm × 12 cm MMCGT agar plates containing 100 μg/ml of 141 kanamycin. 6 mm sterile paper discs impregnated with the 10 μl DMSO extract sample were applied to 142 the surface of the freshly spread plates, and activity scored after incubation at 30 °C for 2-4 days. 143 produce a halo of kanamycin-resistant growth around the paper disc. The number of isolates tested for 145 the first-round screening was over 5,300, with ~260 strains (about 5%) giving a positive response. 146
These positive extracts were subjected to a second-round of screening using the ∆femX mutant strain to 147 identify those containing glycopeptide antibiotics capable of inducing van gene expression (explained 148 in detail in the Results section). Approximately 10 7 spores of S. coelicolor ∆femX mutant strain J3130 149 (see Table S1 ) were spread on MMCGT agar medium containing no antibiotic, and 10 μl DMSO 150 solutions of the selected inducer extracts were applied on paper discs to the plate. Plates were incubated 151 at 30 °C for 2-4 days. Positive inducers produced a halo of glycopeptide-dependent growth of S. 152 coelicolor ∆femX around the disc. 153
A single strain, designated as Amycolatopsis species MJM2582, was isolated from the 260 tested 154 from the first round screen. Among the 9 different extracts from MJM2582 tested, very strong and clear 155 induction halo were all observed from extracts prepared from aqueous and methanol extracts. In 156 contrast, negligible halos were observed from extracts prepared from the ethyl acetate layer. This is 157 consistent with the water solubility and organic solvent insolubility of glycopeptide antibiotics. 158 159 Genomic DNA extraction, sequencing and annotation. 160
The genomic DNAs of MJM2582 and Amycolatopsis lurida were isolated by modification of the 161 'Kirby mix procedure' according to the method described previously (18). Each strain was cultured in 162 10 ml Tryptic Soy Broth (TSB, Oxoid) liquid medium at 30 °C 280 rpm for 2 days. The harvested 163 mycelia were washed twice with an equal volume of 10.3% sucrose and then lysed in 1 ml of lysozyme 164 solution (2 mg/ml lysozyme in 10.3% sucrose, 25 mM Tris (pH8), 25 mM EDTA, pH8) by incubating 165 at 30 °C for 10 min. The lysate was extracted with 1 ml of 2 × Kirby mix (2 g sodium tri-166 isoprophylnaphthalene sulphonate, 12 g sodium 4-amino-salicylate, 5 ml 2 M tris-HCl (pH8), 6 ml 167 8 phenol mixture and made up to 100 ml with water) and 2 ml of phenol/chloroform solution 168 (phenol:chloroform (1:1 v/v), equilibrated with 0.1M Tris, pH8), and 1 ml of phenol/chloroform. The 169 nucleic acids in upper phase were transferred to a fresh tube and precipitated with 1/10 volume of 3 M 170 sodium acetate (pH6) and an equal volume of isopropanol at room temperature for 10 min. The pellet 171 of nucleic acids obtained by centrifugation was then resuspended in RNase solution (50 μg/ml of 172 RNaseI in 500 μl Tris-EDTA (TE) buffer) and incubated for 30 min at 37 °C to remove all RNAs. The 173 genomic DNA sample was cleaned by extraction with 200 μl of phenol/chloroform, and isopropanol 174 precipitation as described above. The DNA pellet obtained after centrifugation was washed with 70% 175 ethanol and dissolved in TE buffer solution (25 mM Tris (pH7.5), 2 ml EDTA Table S3 ). 2.5 ml of dense seed culture was 199 then used to inoculate 50 ml SAM medium in 250 ml Erlenmeyer flasks containing spring wire baffles. 200
After incubation at 30 °C for 6 days with shaking at 250 rpm, the culture broth was centrifuged and the 201 cell pellet was extracted with 1% NH 4 OH (1 ml per 1 g wet pellet). This mixture was centrifuged and 202 the alkaline supernatant harvested and neutralized with HCl. This pellet extract was used for initial 203 bioassay screening and a similar process was used to obtain glycopeptide extracts from S. toyocaensis 204 and A. balhimycina. 205
The MJM2582 glycopeptide was further purified by combining its pellet extract with the culture 206 supernatant, which was then applied to Diaion HP20 resin. The resin was washed with a step-wise 207 gradient of water and methanol to elute the bound glycopeptides (50-80% methanol). Fractions 208 containing glycopeptides were pooled and further purified using a D-Ala-D-Ala affinity resin. This was 209 prepared and used as previously described (30) 
RESULTS
245
Extensive screening of microbial extracts library using a novel two-step bioassay system 246 identified an Amycolatopsis strain producing glycopeptide antibiotic. 247
For this study, we have initially established a geographically diverse collection of actinomycte strains. 248
Each actinomycte strain was then cultured in three different liquid media and extracted with three 249 different solvents consequently generating a total nine different natural product extracts. A randomly 250
selected subset of this library covering ~5,300 actinomycete isolates was screened using a two-step 251 procedure involving an initial bioassay using a sigEp-neo fusion reporter strain to identify extracts 252 capable of triggering a generalized cell wall stress response (10), followed by a growth assay using a 253 ∆femX mutant strain to identify specific glycopeptide antibiotic activity (11, 12) (Fig. 1A) . sigE 254 encodes an extracytoplasmic function (ECF) sigma factor, σ E , which is part of a signal transduction 255 system that senses and responds to cell wall stress and is therefore required for normal cell wall 256 integrity in S. coelicolor (31). Expression of sigE is induced by a wide-variety of agents that stress the 257 cell wall, and wild-type S. coelicolor harbouring a multi-copy sigEp-neo fusion reporter plasmid 258 (pIJ6880; see Table S1 in the supplemental material) in which the aminoglycoside phosphotransferase 259 gene (neo) is expressed under the control of the sigE promoter only exhibits kanamycin-resistant 260 growth in the presence of such compounds (Fig. 1B) . About 5% of the extracts tested strongly activated 261 expression of the sigEp-neo fusion, and these were subjected to a second round of screening using a 262 ∆femX mutant bioassay system. FemX adds a single branched glycine to the stem pentapeptide of12 peptidoglycan precursors during cell wall biosynthesis, and is essential for growth under normal To fully characterize the glycopeptide produced by MJM2582, a draft genome sequence was produced 283 to access the genes in the biosynthetic cluster, and culture extracts were analyzed using LC-MS. 284
Comparative analysis using sequences from a number of previously reported glycopeptide biosynthetic 285 clusters including teiocoplanin (32), balhimycin (33), A47934 (34), dalbavancin (35) and vancomycin 286 (36), indicates that MJM2582 carries a novel ~79 kb gene cluster consisting of 39 Orfs ( Bacterial class C GTs catalyze mannosylation using undecaprenyl-phospho-mannose as a donor, 306 whereas class B GTs utilize a wide variety of NDP-activated sugars (38). The sugars required for 307 ristocetin production can all be accessed from generalized bacterial metabolism with the notable 308 exception of L-ristosamine, a rare dideoxy sugar that requires dedicated genes in the cluster for its 309 biosynthesis. We propose a route to TDP-activated L-ristosamine via activity of the enzymes encoded 310
by Orfs 30-33 in the cluster (Fig. 6 ). These are homologous to genes in the chloroeremomycin cluster 311 additionally requiring a 3-C-methyltransferase (MT) that is absent from the ristocetin cluster. Another 313 unusual feature of ristocetin is its methylation pattern: O-methylation of the carboxyl terminus of the 314 core peptide and C-methylation of (S)-3,5-dihydroxyphenylglycine (Dpg) at amino acid position 3. 315 Accordingly, two MTs are encoded in the gene cluster (see Fig. 3 ). Orf19 shares significant homology 316 with VEG18 which catalyses the C-terminal O-methylation of a glycopeptide aglycone (40) while 317
Orf23 does not share homology with any previously characterized glycopeptide MTs and is therefore 318 the candidate for the C-methylation of the ristocetin aglycone (see Table S4 in the supplemental 319 material). This modification is unique amongst characterized glycopeptide pathways. 320
The four non-ribosomal peptide synthetase (NRPS) proteins in the ristocetin gene cluster have a 321 similar domain organization and predicted adenylation domain specificity to the teicoplanin NRPS and 322 assemble a peptide from β-hydroxytyrosine (βHTy), (S)-4-hydroxyphenylglycine (Hpg) and Dpg (Fig.  323 7; see also Table S5 in the supplemental material) (41). The rigid teicoplanin-like ristocetin aglycone is 324 then predicted to be generated by four cytochrome P450 enzymes encoded by adjacent genes (Orfs12-325 15), which in previously characterized pathways are known to form oxidative cross-links between the 326 aromatic amino acid side chains (32). Interestingly, while the organization of the NRPS into four 327 proteins with a module distribution of 2-1-3-1 is a feature common to teicoplanin-like (Type IV) 328 glycopeptides, the organization of the tailoring enzymes is much more closely related to vancomycin-329 like (Type I) glycopeptides. Furthermore, while Dpg and Hpg biosynthesis is conserved between the 330 production of teicoplanin-like and vancomycin-like glycopeptides, distinct routes have evolved for 331 βHTy biosynthesis, where a single non-heme dioxygenase is used for the former (42), and three 332 separate enzymes for the latter (43). Ristocetin employs the same route as vancomycin (Orfs 25-27), 333 despite a teicoplanin-like aglycone. Ristocetin is the only non-chlorinated glycopeptide antibiotic 334 reported to date, and the gene cluster unsurprisingly does not encode a halogenase. 335 resistance system required for reprograming cell wall peptidoglycan biosynthesis (see Fig. 3 ). However 337 no genes encoding the VanRS two-component regulatory system were identified anywhere in both the 338 MJM2582 and S. lurida genome, implying that vanHAX expression may be constitutive in this strain or 339 otherwise controlled in a VanRS-independent manner. Interestingly, alignment of the vanHAX 340 promoter sequence in ristocetin gene cluster with similar sequences from other glycopeptide gene 341 clusters identified conserved nucleotide changes in those with no obvious VanRS control system in 342 comparison to those known to be regulated by VanRS (Fig. 8) . This implies that the putatively VanRS-343 independent promoters may share the same method of regulation. the producing microbe and the bioactivity of the molecules that are ultimately being sought introduces 363 a number of formidable technical challenges. Our focused approach has the advantage that any positive 364 screen hit apriori comes from an actinomycete strain which is both culturable and competent for the 365 biosynthesis of the detected antibiotic activity under laboratory conditions. 366
We envisage that the direct relationship between producing organism, genome sequence and 367 antibiotic activity afforded by our screening procedure will facilitate both the isolation of new 368 glycopeptide antibiotics, and the provision of novel verified enzyme activities for use in synthetic 369 biology approaches to explore the production and design of modified antibiotic structures. In addition, 370 the extracts identified as active in the first round of sigEp-neo screening but inactive in the subsequent 371 glycopeptide screen, and which were not considered further in this work, provide an enriched library 372 from which to seek other classes of natural products active against the bacterial cell wall. The native S. ,300 different isolates were tested in the first round sigEp-neo fusion reporter system, and 260 different isolates gave extracts which acted as strong inducers. Extracts from these 260 isolates were then subjected to a second round of screening using ∆femX to identify glycopeptide antibiotics, yielding a single positive isolate designated MJM2582. (B) Plates demonstrating the response of the sigEp-neo, ∆femX reporter systems to antibiotics (numbered list shown). Antibiotics that target DNA gyrase (novobiocin), the ribosome (thiostrepton) or early peptidoglycan biosynthesis (tunicamycin) do not induce the sigEp-neo system, while those targeting late peptidoglycan biosynthesis (bacitracin, moenomycin A, ramoplanin, vancomycin, teicoplanin, ristocetin) do. The amount of novobiocin, thiostrepton and tunicamycin used in the bioassays (30 µg each) is sufficient to produce a halo of growth inhibition when assayed against tunicamycin used in the bioassays (30 µg each) is sufficient to produce a halo of growth inhibition when assayed against S. coelicolor. Extracts obtained from known glycopeptide producer strains (A. balhimycina, S. toyocaensis) and from MJM2582 also induced the sigEp-neo system. Only glycopeptide antibiotics (but not teicoplanin) or extracts containing glycopeptides, including MJM2582, acted as inducers in the ΔfemX bioassay. (C) Bioassay showing the spectrum of activity of the MJM2582 extract against glycopeptide sensitive (∆vanRS), constitutively resistant (∆vanS) and inducibly resistant (M600) strains of S. ceolicolor. A detailed comparison to the previously reported glycopeptide clusters can be found in Fig. S3 and Table S4 in the supplemental material. 
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